Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study using zebrafish, four bisbenzylisoquinoline derivatives were found to protect hair cells from aminoglycoside-induced damage without reducing antibiotic efficacy, potentially leading to therapies for patients undergoing such treatments.

This study found that bisbenzylisoquinoline alkaloids from Stephania cepharantha Hayata stimulated growth in cultured murine hair cells but not in keratinocytes or fibroblasts.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

In this study, an ultra-low dose combination of estradiol and dydrogesterone significantly reduced hot flushes and improved health-related quality of life among a multi-ethnic population of postmenopausal women, with no notable difference in serious adverse events compared to placebo.

This review identified two promising therapeutic targets for drug repurposing to treat refractory angina in patients with angina pectoris without obstructive coronary artery disease: endothelin-1 receptor blockers and soluble guanylate cyclase stimulators.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.

This review discusses the historical development, mechanisms of action, and potential new clinical applications of the drug cepharanthine, highlighting its multi-faceted pharmacological properties; it reports no new clinical results.

This study found that two novel nonsteroidal derivatives inhibited specific enzymes in vitro and in vivo, leading to dihydrotestosterone accumulation in androgen-dependent glands, suggesting potential therapeutic use for mood improvement in the elderly.

This study found that torilin from Torilis japonica fruit extract inhibited 5 alpha-reductase in vitro more effectively than alpha-linolenic acid but less effectively than finasteride.

This study investigated the metabolic pathways of epristeride, a new Type II 5α‐reductase inhibitor, using in vitro models and found that its metabolites show significant interactions with key proteins, suggesting implications for its role in doping control.

This study conducted molecular docking and ADME property analysis on 144 newly designed isatin analogs, suggesting they exhibit lead-like properties for targeting EGFR enzymes.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This study identified the N-(iodopropenyl) derivative 13 as a promising candidate for development as a radioiodinated androgen receptor ligand due to its binding affinity.

This study developed a new competitive 5alpha-reductase inhibitor with an IC(50) of 0.84 microM using a novel chemical structure.

This review discusses recent advancements in hair rejuvenation strategies and assesses the potential of herbal drugs as safer alternatives, but reports no new clinical results.

This study found that supraphysiological doses of testosterone alter endothelial relaxation pathways in hypertensive rats, with varied contributions from nitric oxide, prostanoids, and endothelium-derived hyperpolarizing factors, influenced by estrogen and dihydrotestosterone levels.

This study used molecular docking to identify stiripentol as a potential new inhibitor of the SRD5A2 enzyme, which is targeted for treating androgen-related diseases; however, in vivo trials are needed to validate its efficacy.

This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.

This study found that a novel thiohydantoin derivative, 3a, effectively inhibited androgen receptor activity in LNCaP cells and showed promising in vivo results by reducing testosterone-induced prostate changes, outperforming finasteride in mitigating prostate index and histopathological alterations.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

Testosterone, 4-hydroxyandrostenedione, and finasteride affect blood clotting differently in stressed heart conditions.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.